Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

NCT06939127 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy
PROCEDURE: Surgery
DRUG: Adjuvant tislelizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital